PATENT CLAIM ANALYSIS

Application Number: 16046429
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "231100"]

Abstract:
The disclosed invention is related to methods, compositions, kits and isolated nucleic acid sequences for targeting Herpes Simplex Virus (HSV) nucleic acid (e.g., HSV-1 and/or HSV-2 nucleic acid). Compositions include amplification oligomers, detection probe oligomers and/or target capture oligomers. Kits and methods comprise at least one of these oligomers.

Claim (Index 21):
A method for determining the presence or absence of Herpes Simplex Virus 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2) in a sample, said method comprising:\n (1) contacting a sample, said sample suspected of containing HSV-1 or HSV-2, with at least two oligomers for amplifying a target region of an HSV-1 target nucleic acid and at least two oligomers for amplifying a target region of an HSV-2 target nucleic acid, wherein the at least two amplification oligomers for amplifying a target region of an HSV-1 target nucleic acid comprise\n (a) a first amplification oligomer comprising a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:31 and that includes at least the sequence of SEQ ID NO:30; and \n (b) a second amplification oligomer comprising a second target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:33 and that includes at least the sequence of SEQ ID NO:32; \n and wherein the at least two amplification oligomers for amplifying a target region of an HSV-2 target nucleic acid comprise\n (c) a third amplification oligomer comprising a third target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides (i) contained in the sequence of SEQ ID NO:49 and that includes at least the sequence of SEQ ID NO:48 or (ii) contained in the sequence of SEQ ID NO:43 and that includes at least the sequence of SEQ ID NO:42; and \n (d) a fourth amplification oligomer comprising a fourth target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides (i) contained in the sequence of SEQ ID NO:51 and that includes at least the sequence of SEQ ID NO:50 or (ii) contained in the sequence of SEQ ID NO:45 and that includes at least the sequence of SEQ ID NO:44; \n (2) performing an in vitro multiplex nucleic acid amplification reaction, wherein any HSV-1 or HSV-2 target nucleic acid present in said sample is used as a template for generating an HSV-1 or HSV-2 amplification product, respectively; and (3) detecting the presence or absence of the HSV-1 amplification product and the presence or absence of the HSV-1 amplification product, thereby indicating the presence or absence of HSV-1 and HSV-2 in said sample.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 95.0
- Lexical Diversity: 1.39535
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15487240', '14395039', '14441815', '13642428', '14113880']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7789005695631837
- 35 USC 102 Novelty (BERT): 0.5731097773483074
- Combined Prediction Score: 0.758321490341696
- Mean Citation Score: 417.629316
- Max Citation Score: 471.57626
- Similarity Product: 420.8506884737657

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test